A new study has found that patients treated with hydroxychloroquine as well as a combination of the malaria drug with an antibiotic, had higher survival rates.
This study is however quite contradictory as many other studies have found no “beneficial effects” of the use of the drug. For instance a study by researchers at Oxford University found no effect in treating patients with HCQ in a study of 1,542 COVID-19 patients published June 5 as part of the school’s virus study called the “RECOVERY Trial.”
“We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19,” wrote professors Peter Horby and Martin Landray, chief investigators of the RECOVERY Trial. “We have therefore decided to stop enrolling participants to the hydroxychloroquine arm of the RECOVERY Trial with immediate effect.”
The widespread media coverage of this study led other organisations like the WHO,National Institutes of Health and generic HCQ producer,Novartis, to stop their clinical trials, citing a lack of benefits for patients and issues with patient enrollment.
Sanofi, a French pharmaceutical company that produces the anti-malaria drug, also stopped its clinical trial of HCQ.
Still, doctors and recovered COVID-19 patients alike continue to tout the drug’s effectiveness despite the studies.
Henry Ford researchers attribute the difference between the effectiveness of HCQ in their study compared to the ineffectiveness of the drug in other studies to timing and procedure.
“The benefits of hydroxychloroquine in our cohort as compared to previous studies may be related to its use early in the disease course with standardized, and safe dosing, inclusion criteria, comorbidities, or larger cohort. … Later therapy in patients that have already experienced hyperimmune response or critical illness is less likely to be of benefit,” they wrote.